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Abstract
Objectives—Glycosylation or the modification of a cellular component with a carbohydrate 
moiety has been demonstrated in all three domains of life as a basic post-translational process 
important in a range of biological processes. This review will focus on the latest studies 
attempting to exploit bacterial N-linked protein glycosylation for glycobiotechnological 
applications including glycoconjugate vaccine and humanised glycoprotein production. The 
challenges that remain for these approaches to reach full biotechnological maturity will be 
discussed.
Key findings—Oligosaccharyltransferase-dependent N-linked glycosylation can be exploited to 
make glycoconjugate vaccines against bacterial pathogens. Few technical limitations remain, but it 
is likely that the technologies developed will soon be considered a cost-effective and flexible 
alternative to current chemical-based methods of vaccine production. Some highlights from 
current glycoconjugate vaccines developed using this in-vivo production system include a vaccine 
against Shigella dysenteriae O1 that has passed phase 1 clinical trials, a vaccine against the tier 1 
pathogen Francisella tularensis that has shown efficacy in mice and a vaccine against 
Staphylococcus aureus serotypes 5 and 8. Generation of humanised glycoproteins within bacteria 
was considered impossible due to the distinct nature of glycan modification in eukaryotes and 
prokaryotes. We describe the method used to overcome this conundrum to allow engineering of a 
eukaryotic pentasaccharide core sugar modification within Escherichia coli. This core was 
assembled by combining the function of the initiating transferase WecA, several Alg genes from 
Saccharomyces cerevisiae and the oligosaccharyltransferase function of the Campylobacter jejuni 
PglB. Further exploitation of a cytoplasmic N-linked glycosylation system found in Actinobacillus 
pleuropneumoniae where the central enzyme is known as N-linking glycosyltransferase has 
overcome some of the limitations demonstrated by the oligosaccharyltransferase-dependent 
system.
Summary—Characterisation of the first bacterial N-linked glycosylation system in the human 
enteropathogen Campylobacter jejuni has led to substantial biotechnological applications. 
Alternative methods for glycoconjugate vaccine production have been developed using this N-
linked system. Vaccines against both Gram-negative and Gram-positive organisms have been 
developed, and efficacy testing has thus far demonstrated that the vaccines are safe and that robust 
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immune responses are being detected. These are likely to complement and reduce the cost of 
current technologies thus opening new avenues for glycoconjugate vaccines. These new markets 
could potentially include glycoconjugate vaccines tailored specifically for animal vaccination, 
which has until today thought to be non-viable due to the cost of current in-vitro chemical 
conjugation methods. Utilisation of N-linked glycosylation to generate humanised glycoproteins is 
also close to becoming reality. This ‘bottom up’ assembly mechanism removes the heterogeneity 
seen in current humanised products. The majority of developments reported in this review exploit 
a single N-linked glycosylation system from Campylobacter jejuni; however, alternative N-linked 
glycosylation systems have been discovered which should help to overcome current technical 
limitations and perhaps more systems remain to be discovered. The likelihood is that further 
glycosylation systems exist and are waiting to be exploited.
Keywords
glycoconjugates; humanised glycoproteins; PglB; vaccines
Introduction
Glycoconjugate vaccines
The majority of bacterial pathogens are coated with a carbohydrate moiety. Unsurprisingly, 
upon infecting a host, these carbohydrates are often the very first epitopes detected by the 
immune system. The idea that surface carbohydrates from bacterial pathogens may serve as 
vaccines has been around since the 1920s. However, in the majority of patients, this 
carbohydrate component alone is insufficient to generate a long lasting immune response. 
Most polysaccharides are considered T-cell independent antigens,[1] unable to induce IgM to 
IgG switching, and to sustain T-cell memory.
Particularly at-risk populations are children under the age of 5 and the elderly. In young 
children, the reason for this weakened immune response is thought to be due to immature B 
cells with reduced CD21 expression, and reduced concentrations of IgG2 which are required 
to react to polysaccharide antigens.[2] In the elderly population, there is a limited magnitude 
of antibody responses to polysaccharides; the reason for this weakened response is thought 
to be due to a low reservoir of IgM+ memory B cells and their weaker differentiation into 
antibody producing cells.[3]
The discovery by Oswald Avery and Walter Goebel in 1929 that a specific polysaccharide 
functioned only as a true antigen when attached with some other constituent of the cell was 
ground breaking. Just as insightful was the demonstration that asymmetry in the sugar 
component alone, a switch of glucose and galactose, could lead to distinct serological 
responses.[4]
The latter finding gave the scientific community a glimpse into how infection with two 
seemingly identical bacteria with distinct sugar structures could give rise to such different 
immunological responses.
These were the foundations for glycoconjugate vaccinology. Surprisingly, however, no 
glycoconjugate vaccine was licensed for almost 60 years. In 1987, a vaccine directed against 
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Haemophilus influenzae type b (Hib) was licensed and was based on the attachment of the 
polyribosylribitol phosphate capsular polysaccharide to various immunogenic carrier 
proteins.[5,6]
The global vaccine market is projected to be worth approximately US $30 billion by 2015; 
of this total, glycoconjugate vaccines will make up more than US $7 billion. However, 
production is expensive and time consuming. The accepted technique to make 
glycoconjugate vaccines is chemical conjugation; polysaccharides are chemically activated 
at random sites, or alternatively at the reducing end.[7] There are a multitude of options to 
link the glycan to the carrier protein. However, they all require initial steps to strip the 
polysaccharide from the pathogenic organism against which the vaccine is targeted: removal 
of contaminating endotoxin, purification of the acceptor protein from the organism of 
choice, before protein and glycan are treated to link the two to make the final 
glycoconjugate. Preparation of the acceptor protein is often not a simple procedure, for 
example, the carrier protein CRM197 used to be isolated from the culture supernatant of 
Corynebacterium diphtheriae, which required dedicated biosafety level 2 facilities with 
appropriate containment.[8]
These methods work; however, production is a multistep process and requires several rounds 
of purification to ensure that the glycoconjugate has been assembled correctly, therefore 
rendering glycoconjugate vaccine production an expensive process and prone to batch-to-
batch variation (Figure 1).
Hib vaccine—H. influenzae is a non-motile Gram-negative coccobacillus; it can cause 
considerable morbidity and mortality with disease presentations such as meningitis, 
pneumonia, osteomyelitis, epiglottis and otitis. The bacterium is carried in the upper 
respiratory tract and is transmissible from person to person via aerosols.
The impact of Hib glycoconjugate vaccination has been impressive; in 2000, Hib caused an 
estimated 8–13 million serious illnesses and 371 000 deaths worldwide, most of these in 
developing countries.[9] In the absence of vaccination, the global incidence of Hib 
pneumonia was 1304 per 100 000 children younger than 5 years.[9] In countries where Hib 
glycoconjugate vaccination has been introduced such as the United Kingdom, this rate has 
declined to approximately 0.6 per 100 000 in children younger than 5 years.[10]
Streptococcus pneumoniae vaccine—S. pneumoniae is a Gram-positive coccus and a 
major cause of bacterial meningitis, sepsis and pneumonia. The organism is carried in the 
upper respiratory tract of approximately 5% of the world’s population and is transmitted via 
droplet spread. It is estimated that up to one million children die each year from S. 
pneumoniae infection. The greatest challenge for vaccine manufacture is that there are over 
>90 serotypes, based on capsular polysaccharide structure.[11] In 2000, a glycoconjugate 
vaccine targeting seven of the most prevalent serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) 
conjugated to CRM197 (a detoxified version of diphtheria toxin, generated by a single amino 
acid substitution from glycine 52 to glutamic acid) was introduced in the United States. This 
resulted in a 73% decrease in hospital admissions for pneumonia in children aged below 5 
years old, and a 39% decrease in children below the age of 2.[12] Despite this excellent 
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efficacy and the subsequent generation of 10 and 13 valent glycoconjugate vaccine 
formulations, the number of children dying each year remains high, particularly in 
developing countries. This is partly due to the cost of manufacturing the vaccine, the 
complexity of such a varied number of serotypes and the fact that there is different serotype 
prevalence in different parts of the world.
Neisseria meningitidis vaccine—N. meningitidis is a Gram-negative diplococcus with 
13 distinct capsule types (A, B, C, D, 29E, H, I, K, L, W135, X, Y and Z). The highest 
incidence rates in the world occur within an area known as the ‘meningitis belt’ in Sub-
Saharan Africa that spans from Senegal to Ethiopia. The organism is a major cause of 
meningitis with considerable morbidity and mortality worldwide. The organism is carried in 
the nasopharynx of at least 10% of the general population and is spread through person to 
person contact, such as inhalation of respiratory droplets from the nose and throats of 
infected persons. Within the meningitis belt region of Africa, disease rates have been 
reported to reach 1000 per 100 000 population.[13] In Africa, the majority of cases are 
caused by serotype A while in Europe, N. meningitidis serotype B appears to be the major 
causative agent of disease. A serogroup A polysaccharide (a homopolymer of 2-
acetamido-2-deoxy-D-mannopyranosyl phosphate)[7] conjugated to tetanus toxoid known as 
MenAfriVac was licensed in India in 2009 and prequalified by the World Health 
Organisation in 2010. Early tests in one of the endemic countries, Chad, indicates that 
meningitis rates in unvaccinated regions reached 43.8 per 100 000 while in vaccinated 
regions, it dropped to 2.48 per 100 000. Moreover, none of the reported cases in vaccinated 
regions appear to be due to serotype A.[14]
How glycoconjugate vaccines generate the desired immune response
Glycoconjugate vaccines provide enormous health benefits and superior immunity compared 
with polysaccharides alone, especially in the <5-year-old age group, the elderly and the 
immunocompromised. By attaching the sugar moiety to a typical T-cell dependent antigen 
such as a protein, the glycoconjugate becomes capable of inducing formation of 
polysaccharide-specific IgM to IgG switching, memory T-cell proliferation and memory B 
cell development. Despite this knowledge, a working model explaining why a 
glycoconjugate could provide such a response has been difficult to elucidate.
In 2011, Avci et al.[15] presented a plausible working model; one that appears to indicate 
that the glycoconjugate bound to a T-cell receptor was internalised and, in the endosome, 
was broken down into smaller peptides. Crucially, both the peptide and polysaccharide are 
trimmed allowing for binding of a glycopeptide to major histocompatibility complex (MHC) 
class II and presentation of this moiety to the T cell. This model appears to answer the 
conundrum as to why the protein and the sugar must be covalently bound to induce the 
optimal immune response (Figure 2).
The model also provides important clues as to how current glycoconjugate vaccines could be 
improved by rationally designing the protein carrier and the glycan attached to it. It may be 
possible that, by first identifying which shortened peptides are presented to the T-cell 
receptor by MHC class II, one may be able to reduce the size of the carrier, making protein 
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expression and purification much easier and cheaper. It also indicates that the location of the 
sugar-peptide glycosidic bond is absolutely critical and that the next generation of 
glycoconjugate vaccines may be designed based on this location.
Glycoproteins in bacteria
The post-translational modification of proteins with glycan structures was for many years 
thought to be a feature unique to eukaryotic organisms. In 1976, the first study was 
published indicating that glycoproteins were present also in bacteria. Sleytr and Thorne 
analysed the surface layers of Clostridium thermasaccharolyticum and C. 
thermohydrosulfuricum and revealed that the proteins making up these surface layers were 
glycosylated.[16] We now understand that protein glycosylation systems are abundant in 
bacteria and that they can be separated into separate classes. For example, glycans can 
covalently attach to asparagine (N-linked) or serine/threonine residues (O-linked); they can 
modify single, or multiple proteins; glycans can be added sequentially or en bloc; and 
glycosylation can occur in different compartments of the cell. Additionally, they often 
involve oligosaccharyltransferases (OTases), a family of glycosyltransferases that catalyse 
the transfer of an oligosaccharide from a lipid donor to an acceptor molecule, usually a 
protein. Recent studies have demonstrated at least four classes of protein glycosylation 
systems in bacterial pathogens. These include two evolutionary distinct N-linked general 
glycosylation systems: one typified by the Campylobacter jejuni PglB system, where en bloc 
glycosylation operates in the periplasm through an N-OTase[17] and the other by the H. 
influenzae N-glycosyltransferase system where sequential glycosylation operates in the 
cytoplasm.[18,19] Similarly, there are en bloc and sequential O-glycosylation pathways 
typified by the Neisseria PglL periplasmic system, which requires an O-OTase[20] and the 
surface glycosylation of Escherichia coli AIDA-1 adhesins that is OTase independent.[21]
The expanding bacterial sequence dataset coupled with developments in mass spectrometry 
and analytical glycosciences has identified protein glycosylation systems in most bacterial 
pathogens. Indeed, many bacterial species have multiple glycosylation systems. However, 
despite their potential therapeutic importance, bacterial glycosylation systems remain largely 
uncharacterised, partly due to the complexity of the glycostructures. Thus, bacterial 
glycosylation represents an important but largely unexplored frontier in microbial science.
PglB the first bacterial N-linking OTase
Sequencing of the human gut pathogen C. jejuni NCTC 11168 in 2000 confirmed the 
presence of a genetic locus previously identified in C. jejuni 81-176 that looked like a 
polysaccharide coding region.[22-24] Within this polysaccharide coding region, an open 
reading frame that has significant similarity to an OTase subunit called STT3 involved in 
protein glycosylation in Saccharomyces cerevisiae was found. The region was tentatively 
named pgl for protein glycosylation locus and the OTase orthologue, PglB. Studies over the 
last 14 years have revealed the function of the locus in making a heptasaccharide with the 
structure GalNAc-α1,4-GalNAc-α1,4-[Glcβ1,3-]GalNAc-α1, 4-GalNAc-α1,4-GalNAc-
α1,3-Bac-β1 where Bac is bacillosamine or 2,4-amino 2,4,6 trideoxy-D-glucose, GalNAc is 
N-acetylgalactosamine and Glc is glucose.[25,26] Crucially, these studies also revealed that 
PglB was an OTase and that the similarity in function meant that it was the first OTase 
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identified in bacteria that could modify asparagines residues within a protein. The enzyme 
was found to accept diverse glycans when heterologously expressed in E. coli[27,28] and the 
amino acid sequence on an acceptor protein required for glycan modification was similar to 
that seen in the eukaryotic STT3 counterpart. The eukaryotic enzyme recognises an N-X-S/T 
sequon where is X is any amino acid except for proline, while substrate proteins for PglB 
require a negatively charged residue at the −2 position, extending the sequon to D/E-X1-N-
X2-S/T where X is any amino acid except for proline.[28] The presence of an aspartic acid or 
a glutamic acid at the −2 position is an interesting difference between the eukaryotic and 
prokaryotic counterpart, since in eukaryotes, the presence of an acidic residue near the 
glycosylation site is disfavoured.[29] Currently, an absolute requirement of both eukaryotic 
and prokaryotic counterparts (including C. jejuni PglB) is the presence of an acetamido 
group at the C2 position of the reducing end sugar.
Experiments demonstrated that proteins that did not have native glycosylation sequons could 
become glycosylated with the addition of a glycosylation sequon. This was demonstrated 
elegantly in the glycosylation of cholera toxin[30] and green fluorescent protein, also 
indicating that the glycosylation motif must be present within an accessible domain such as 
a flexible loop within a nascent polypeptide, in order for it to be accessible to PglB.[31]
More recently, the structure of PglB was elucidated from Campylobacter lari. 
Crystallisation of the enzyme in complex with a peptide consisting of DQNATF (the optimal 
acceptor peptide for PglB)[32] revealed 13 transmembrane domains and provided some clues 
to indicate that the extended acceptor sequon may be necessary for tighter peptide binding. 
For the first time, a plausible working model of how PglB functions is possible and is 
explained in great detail in Lizak et al.[33]
The advent of next generation sequencing has revealed that PglB is not unique to the 
Campylobacter species but is present in a large number of epsilonproteobacteria, including 
deep sea vent organisms such as Nitratiruptor tergarcus. This finding makes it tempting to 
speculate that perhaps this type of protein modification evolved to enable proteins to have 
higher thermotolerance. The abundance of STT3 orthologues extends outside this 
subdivision to deltaproteobacteria and also archae,[34] and provides a source of enzymes that 
may have different specificities to the C. jejuni PglB currently being utilised.
The discovery of the N-linked glycosylation system in C. jejuni is forerunner in 
glycoconjugate vaccine generation. To fully appreciate the biotechnological applications of 
OTases such as PglB, one needs only to compare the mechanism of heptasaccharide 
assembly in C. jejuni and typical O-antigen biosynthesis (Figure 3).
This is an in-vivo approach to generate glycoconjugate vaccines and has a number of 
advantages when compared against current chemically conjugated vaccines. Firstly, 
following subcloning of the required genetic content coding for the polysaccharide of 
choice, the entire process of glycoconjugate production can be transferred into a safe, 
laboratory strain of E. coli. This means that the glycoconjugate can conceivably be made 
without ever coming into contact with the pathogenic organism. The polysaccharide 
component and the carrier protein are linked in vivo, meaning that they do not have to 
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undergo any purification steps before attachment, rendering the process much cheaper when 
compared with in-vitro conjugation. Once the three plasmid system is transformed into an E. 
coli strain, an inexhaustible supply of homogenous glycoconjugate is produced. Finally, the 
system has built-in flexibility. If the carrier protein or glycan need to be changed, then a 
simple plasmid swap is undertaken, meaning that multiple glycoconjugate combinations 
could be assembled and tested rapidly.
The technology has been used to make a glycoconjugate using the Shigella dysenteriae 
serotype O1 O-antigen repeat unit and attaching it to a detoxified form of Pseudomonas 
aeruginosa exotoxin A (EPA).[35] In February 2010, GlycoVaxyn, a company based on the 
utilisation of PglB to make glycoconjugate vaccines, reported that phase 1 clinical trials had 
begun using the S. dysenteriae O1-EPA conjugate, and in October of 2010, they reported 
that the conjugate demonstrated excellent safety profiles and that robust immune responses 
were elicited. More recently, initiation of phase 1 clinical trials on a vaccine developed 
against extra-intestinal pathogenic E. coli was announced (www.GlycoVaxyn.com, Press 
release).
The technology has been exploited by the Wren laboratory to generate a glycoconjugate 
vaccine against Francisella tularensis subs. tularensis by linking the O-antigen repeat unit 
to EPA.[36] The most recent breakthrough has been the utilisation of this technique to make 
a capsular polysaccharide glycan from a Gram-positive organism, Staphylococcus aureus 
serotypes 5 and 8 within E. coli. The flexibility of this technology is best demonstrated in 
this latest study where the acceptor protein was switched from EPA to a S. aureus toxoid 
HlaH35L that resulted in superior vaccine efficacy.[37]
One of the difficulties related to the use of PglB, in glycoconjugate vaccine design, is the 
assignment of a glycosylation sequon to a particular site within a protein. This meant that to 
find a location accessible for modification, partial or predicted structural information will be 
required. This problem was addressed by Fisher et al. who demonstrated that a D/E-X1-N-
X2-S/T acceptor sequon could be added to the C- or N-terminus of a protein to render it a 
target for glycosylation.[38] The malE gene coding for maltose-binding protein was cloned 
and expressed in E. coli with four glycosylation tags (GT). Expression of malE alongside the 
entire pgl locus from C. jejuni resulted in tetraglycosylated material, indicating that every 
GT was occupied.
This technique, also known as protein glycan coupling technology (PGCT), may for the first 
time enable the cheap manufacture of glycoconjugate vaccines aimed at bacterial animal 
pathogens. Very few attempts have been made to generate such vaccines due to the 
prohibitive cost of manufacture, but examples exist generated through chemical conjugation, 
that show efficacy. In the swine pathogen Actinobacillus pleuropneumoniae serotype 1, the 
capsular polysaccharide and the O-antigen were chemically conjugated to the haemolysin 
protein from the same organism. Following vaccination, pigs were found to have 
significantly increased IgG antibodies against capsular polysaccharide and 
lipopolisaccharide, and sera from vaccinated pigs were opsonic in phagocytic assays.[39,40]
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A study by Iwashkiw et al. attempting to make a novel glycoconjugate vaccine against 
Brucella abortus, the causative agent of brucellosis, demonstrated that PglB could be 
transformed and expressed directly within a host organism other than E. coli. The authors 
‘hijacked’ Yersinia enterocolitica O9 O-antigen production by introducing PglB into the 
organism because this bacterium shares identical O-antigen structure to B. abortus. 
Transformation of a second plasmid coding for a glycosylatable acceptor protein resulted in 
glycoprotein generation within Y. enterocolitica.[41] This work demonstrated the possibility 
to rapidly obtain glycoconjugate vaccine candidates by introducing PglB directly into host 
organisms and our group among others are attempting this approach.
In summary, glycoconjugate vaccine production using PGCT has enormous potential to 
make a significant impact on bacterial disease, both in humans and in animals. The proof of 
principle experiments have been completed, and a number of vaccines are now in phase I 
clinical trials. There are, of course, considerable hurdles to overcome before vaccines 
generated with this technique become widely available. New vaccines generated against 
human bacterial pathogens require enormous financial backing. Not least for the costs of 
carrying out larger scale, testing of vaccine efficacy and then moving to tens of thousands of 
study participants required for phase 4 trials. However, the evidence is mounting that the 
technology works, and further technical modification are being developed to improve yield 
further.
Humanised glycoprotein production
Bacterial N-linked glycosylation systems are also being exploited to attempt to tap into a 
second multibillion dollar industry, namely generation of humanised glycoproteins. Unlike 
glycoconjugate vaccine production where significant similarities can be observed between 
assembly of the heptasaccharide that modifies C. jejuni proteins and O-antigen biosynthesis, 
the eukaryotic glycoprotein assembly mechanism is quite distinct. N-linked glycosylation in 
eukaryotes begins by assembly on a dolichol phosphate (DolP) lipid carried within the 
cytosolic compartment of the endoplasmic reticulum (ER). A core glycan of 14 units is 
assembled by the addition of monosaccharides through the action of glycosyltransferases. 
This core takes the form of Glc3Man9GlcNAc2 where Glc is glucose, Man is mannose and 
GlcNAc is N-acetyl glucosamine. The dolichol pyrophosphate (DolPP) loaded core sugar is 
flipped to the luminal side of the ER before the OTase transfers it onto a growing 
polypeptide, within the recognition sequon N-X-S/T. This step is important in enabling 
correct protein folding. The core glycan is trimmed within the ER by glucosidases and in 
some cases mannosidases, then enters the Golgi and is trimmed by class I mannosidases to 
generate a smaller core made of a pentasaccharide consisting of two N-acetyl glucosamines 
and three mannose residues. This structure forms the core of eukaryotic glycans; however, it 
can be further altered by various glycosyltransferases to form three groupings of 
modifications known as high mannose, complex and hybrid (Figure 4).[42] High mannose 
types have mannose residues added to the pentasaccharide core, complex types have no 
further mannose residues but have multiple branches with additions of N-acetyl 
glucosamine, and hybrid types have a combination of both mannose and N-acetyl 
glucosamine. Complex and hybrid types can have further additions of fucose and N-acetyl 
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neuraminic acid to increase complexity. It should be stressed that in nature, glycoproteins 
show a high degree of heterogeneity in terms of glycan content and structure.
It is estimated that over half of all eukaryotic proteins are glycosylated and that 90% of these 
carry an N-linked modification. A study utilising mass spectrometry to investigate the 
heterogeneity of human serum N-linked glycosylation revealed that complex type glycans 
made up 96% of the total glycans identified while hybrid and high mannose types made up 
the remainder.[43]
In eukaryotes, N-linked glycosylation plays multiple roles, from correct protein folding, 
stability, intracellular and intercellular trafficking to cell–cell interactions.[44] N-linked 
glycosylation is so important in humans that removal of this type of glycan modification is 
lethal.[45] Glycosylation is so important that 1–2% of our genome is dedicated to encoding 
for enzymes involved in glycan formation[46] and defects in enzymes involved in N-linked 
glycosylation can lead to a host of genetic disorders. For example, mutation of DPM1 
coding for a Dol-P-mannosyltransferase leads to severe mental retardation, epilepsy and 
hypotonia. A host of muscular dystrophies are caused by defects in glycosylation pathways, 
an example is seen in Walker–Warburg syndrome caused by a defect in the O-
mannosyltransferase I enzyme encoded by POMT1/POMT2 which can lead to cerebellar 
malformations, eye abnormalities and death in infancy.
Current manufacture—Sales of therapeutic proteins by pharmaceuticals companies 
reached over $63 billion in 2012; the highest selling class of biologics was made up of 
monoclonal antibodies (mAb), with US sales reaching $24.6 billion. The vast majority of 
these mAb are humanised by the addition of glycan modifications achieved through the 
expression of the protein of interest in mammalian cell lines; examples of such products are 
Actemra (Genentech, San Francisco, CA, USA), an anti IL-2 humanised IgG1k, prescribed 
for the treatment of arthritis. Xgeva (Amgen Inc., Thousand Oaks, CA, USA), the anti-
RANK ligand human IgG2k mAb, prescribed to patients with bone metastases from solid 
tumours. The pharmaceutical company Roche alone has 11 monoclonals on the market,[47] 
demonstrating that the biotech sector is growing and that much of this growth is fuelled by 
glyco-protein production. The proven benefits of adding human-like glycan modifications to 
proteins include enhancing stability, reducing immunogenicity and increasing circulating 
half-life.[48]
When preparing for humanised glycoprotein production, a number of factors must be 
considered: the first is to determine if glycosylation is necessary for the therapeutic profile 
of the target glycoprotein. If not, then one must ascertain if this protein, without glycan 
modification, could become more immunogenic due to peptide unmasking.
If glycan modification is necessary, then one must understand if the glycan epitope can be 
simplified and still achieve full therapeutic activity. Finally, there is the added complexity of 
ensuring that glycosylation can be reproduced faithfully without batch-to-batch variation.[49]
To date, a number of alternative systems are employed to generate proteins with ‘human-
like’ glycan modification. The industry standard is to use mammalian cell line expression 
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systems such as Chinese hamster ovary (CHO) cells. These build the glycan on the same 
DolPP precursor and generate identical core sugar structures to human proteins. However, 
there are considerable difficulties with current approaches that leave the door open for 
alternative, cheaper, efficient, production strategies. Animals and humans differ in their 
glycan modifications when the glycans extend beyond the core pentasaccharide. Humans do 
not have the ability to synthesise N-glycolyneuraminic acid (Neu5Gc) due to an inactivation 
of cmah, coding for CMP-N-acetylneuraminic acid hydroxylase, utilising instead N-acetyl 
neuraminic acid (NeuAc).[50] Humans are also unable to produce N-linked glycans with 
terminal galactose 1–3 galactose residues (α Gal), in contrast to CHO cell lines. These 
modifications are actually immunogenic and high levels of contaminating Neu5Gc in 
proteins have been linked with a reduction in the circulating glycoprotein half-life.[51] 
Correct terminal sialic acid decoration on therapeutic glycoproteins is known to play a role 
in reducing clearance rate, increasing protein stability, reducing immunogenicity and 
increasing enzymatic activity.[52]
There are a number of further complications related to the use of mammalian cell lines. 
Difficulties in scalability mean that the process is expensive, mammalian cells require 
bovine serum albumin for culture of which there is a global shortage and there is also a 
concern of viral disease spread through the use of products generated by this approach.
Humanised glycoprotein production in bacteria—The discovery of PglB and the 
subsequent characterisation of its enzyme capabilities led researchers to speculate that 
humanised glycoprotein production might be a possibility within a prokaryotic host. 
Generation of a humanised glycoprotein within a bacterium is considered a ‘bottom-up’ 
approach because prokaryotic and eukaryotic N-linked glycans are structurally distinct. This 
is an attractive proposition because the method should produce a homogenous glycan 
modification. However, to succeed, a number of technical hurdles must be overcome. 
Transfer of a complete glycan biosynthetic pathway is not plausible primarily because in 
eukaryotes sugars are assembled on DolP while in bacteria polysaccharides are assembled 
on UndP. The specificity of C. jejuni PglB for a longer acceptor sequon (D/E-X-N-X-S/T) 
and the discovery that eukaryotic sites disfavour acidic amino acids near the glycosylated 
asparagines would also mean that the human acceptor protein would likely have to be 
modified, potentially altering protein characteristics. Finally, sugar biosynthetic pathways in 
the prokaryotic host may need to be altered to drive sugar precursors towards the required 
product.
To resolve these limitations, Valderrama-Rincon et al. developed a hybrid approach where 
sugar biosynthesis was initiated using WecA (an initiating transferase used by E. coli to 
generate enterobacterial common antigen) to attach N-acetylglucosamine-1-phosphate 
(GlcNAc-1-phosphate) to UndP. Crucially, this is the same initial sugar seen in eukaryotic 
N-linked glycans and provides a ‘priming’ site onto which glycan biosynthesis may 
progress. The addition of Alg14/13/1/2 from Saccharomyces cerevisiae continued the 
process to make an intact eukaryotic pentasaccharide core (Figure 5). To increase the 
availability of guanosine diphosphate-mannose (GDP-mannose) and aid in the assembly of 
the mannose-containing core, the authors also deleted a GDP-mannose dehydratase, 
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therefore preventing GDP-mannose from continuing its normal conversion to GDP-L-
fucose.
Valderrama-Rincon et al. demonstrate glycosylation of a number of human glycoprotein 
targets, including the Fc domain of IgG1, by adding a native periplasmic signal sequence to 
the human protein and introducing C. jejuni PglB into this E. coli strain. As expected, the Fc 
domain only became glycosylated with the pentasaccharide once the acceptor sequon had 
been modified and extended to DQNAT.
The work demonstrated proof of principle that humanised glycoproteins could soon be 
assembled in E. coli. The elegance of this approach is that by using S. cerevisiae enzymes, 
the linkages between individual sugars were confirmed to be identical to the human N-linked 
glycan core.[53]
The glycan would, most likely still, require a number of additions to generate a complex 
class of modification but this is an impressive starting point. A recent study by Meuris et al. 
indicates that if the therapeutic goal is antigen neutralisation, the epitope could be shortened 
to GlcNAc-Gal–NeuAc,[54] making in-vivo glycoprotein assembly in bacteria a strong 
possibility.
Next generation sequencing technologies have led to the identification of a plethora of PglB 
orthologues, even outside of the epsilonproteobacteria subdivision. Discovery and 
characterisation of a PglB orthologues in the deltaproteobacterium Desulfovibrio 
desulfuricans (PglBDD) revealed that this enzyme could transfer mono- and polysaccharides 
when expressed heterologously in E. coli. Studies also revealed that the enzyme had an 
altered amino acid specificity, requiring only the eukaryotic sequon (N-X-S/T) to be present 
for glycosylation to occur.[34]
A PglB capable of efficiently glycosylating proteins using shortened eukaryotic sequons 
would have clear advantages in making humanised glycoproteins when compared with C. 
jejuni PglB. Unfortunately, PglBDD does not appear to be the answer, as glycosylation 
efficiency is much reduced compared with C. jejuni PglB. In addition, it appears as though 
PglBDD was unable to modify the wild-type CH2 domain of human IgG1.[53] The 
characterisation of other PglB orthologues is expected to eventually resolve this sequon 
dilemma. Alternatively, the structure of C. lari PglB has revealed important clues regarding 
the amino acid residues responsible for extended sequon recognition; this means that there is 
a possibility that C. jejuni PglB could be mutated to make a variant capable of N-X-S/T 
recognition, although it is unknown what influence this may have to glycoprotein yield.[33]
The discovery and characterisation of a cytoplasmic N-linking glycosyltransferase (NGT), in 
the respiratory swine pathogen A. pleuropneumoniae, has also provided an alternative 
approach to in-vivo expression systems. NGT is distinct from PglB because it uses UDP-Glu 
as the sugar substrate and catalyses formation of the glycosidic bond directly onto N-X-S/T 
acceptor sequons within a protein.[55] Lomino et al. demonstrated that using a 
chemoenzymatic approach, the Glc-peptide linkage could be used as a priming site for 
transglycosylation by endoglycosidases. This allowed build up of high mannose, asialylated 
complex and fully sialylated complex bi-antennary glycans, even demonstrating 
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modification of C34, a potent human immunodeficiency virus (HIV) fusion inhibitor derived 
from HIV-1 gp41 envelope glycoprotein.[56] Further work is required to demonstrate the 
efficacy of this approach on a range of human proteins, and the scalability of the process.
Finally, Hug et al. report the generation of a Lewis × (Lex) glycan epitope consisting of 
Galβ1-4[Fucα1-3]GlcNAc (where Fuc is fucose) on a carrier protein to generate a potential 
immunosuppressed protein. The authors utilised the E. coli WecA protein to attach a 
priming GlcNAc onto which the Lex epitope could be completed. This was achieved by 
using glycosyltransferases from the H. influenzae lipooligosaccharide biosynthetic cluster. 
The fucose modification was added in vitro to complete the sugar structure.[57]
Conclusions and future perspectives
This review focused on N-linked glycosylation and Table 1 summarises key publications 
demonstrating utilisation of this modification system; included in these highlights are a 
number of studies that have overcome current technical limitations of humanised 
glycoprotein expression within E. coli by combining in-vivo and in-vitro enzymatic steps. 
Bacteria also carry several O-linked glycosylation systems, and there is also potential for 
these systems to be exploited in the manufacture of glycoconjugate vaccines. O-linked 
OTases are related to WaaL ligase enzymes; the biggest advantage of PglL-based enzymes 
is that they do not have the current C. jejuni OTase limitation of an absolute requirement of 
an acetamido group at the C2 position of the reducing end sugar. Currently however, a 
peptide consensus sequon has yet to be identified meaning that acceptor proteins are strictly 
limited.[20,59]
Bacterial glycosylation systems are also attractive targets for new class of antimicrobials 
that target glycosyltransferases[60] because these systems are often critical for full virulence.
Recent research is providing compelling evidence for protein glycosylation being central to 
the survival and pathogenesis of many bacteria[61-64] and thus represents an ideal target to 
disable them. We consider bacterial glycosylation systems a largely untapped resource to 
counteract the continued threat posed by bacterial pathogens, either through the 
development of novel antimicrobials or via glycoconjugate vaccines. However, to fully 
realise this benefit, and in the longer term to produce recombinant human glycoproteins of 
considerable therapeutic value, a better understanding of the basic mechanisms and 
pathways of bacterial glycosylation is essential. Glycoconjugate vaccine production stalled 
for a number of years, primarily due to the discovery of antibiotics. We are living in an era 
where the rise of multidrug resistant bacteria mean that alternative vaccine formulations are 
desperately needed. This is especially true in susceptible young children within the 
developing world.
The N-linked glycosylation system from C. jejuni is a powerful tool for glycoconjugate 
vaccine development, the most advanced vaccine generated using PGCT, targeting S. 
dysenteriae has passed phase 1 clinical trials, and a glycoconjugate vaccine against extra-
intestinal pathogenic E. coli has commenced phase 1 testing.
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It should be noted that there is potential for this technology to be exploited to develop 
glycoconjugate vaccines against animal pathogens; to achieve this, novel genetic tools are 
being developed and tested by our labs and others.
Alternative uses for bacterial N-linked glycosylation systems are being explored and some 
successes have been reported in the generation of ‘human-like’ glycans. A eukaryotic 
pentasaccharide core can now be assembled using the initiating transferase WecA as the 
starting sugar and combining this with S. cerevisiae glycosyltransferases to build the 
pentasaccharide. However, this technical application is still in its infancy and further 
modifications are required to make full-length humanised glycoprotein. The complexity of 
human glycoproteins is such that the type of modification will likely need to be different 
depending on the target protein being modified and the therapeutic effect aimed for.
Finally, it should be stressed that glycosylation systems are abundant in all kingdoms of life 
and await biotechnological exploitation.
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Figure 1. 
Example of chemical conjugation procedure used to generate glycoconjugate vaccines. In 
this example, production requires purification of lipopolisaccharide (LPS) from Francisella 
tularensis subs. tularensis, endotoxin cleavage, further purification, chemical activation and 
linkage to carrier protein CRM197.
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Figure 2. 
Simplified working model of T-cell activation by glycoconjugate vaccines. The glycan 
portion of the glycoconjugate binds to the B cell receptor (BCR), the glycoprotein is 
internalised into an endosome where the action of reactive oxygen species (ROS) and 
proteases process the glycoprotein into smaller glycopeptides, with shorter polysaccharide 
repeat units. The peptide portion of the newly formed glycopeptide binds to major 
histocompatibility complex (MHC) class II and enables presentation of the hydrophilic 
carbohydrate to the αβ T-cell receptor (αβTCR). Downstream processes enable maturation 
of a B cell to become a memory B cell and produce carbohydrate specific IgG antibodies 
(adapted from Avci et al.[15]). P, peptide; carbohydrate component shown as black circles.
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Figure 3. 
Utilisation of PglB to make glycoconjugate vaccines. (a) Typical O-antigen assembly 
model; glycosyltransferases (GTs) sequentially build polysaccharide on undecaprenyl 
pyrophosphate (black circles), this is flipped into the periplasmic compartment of the cell 
where a ligase (WaaL) transfers the polysaccharide onto a lipid A core, before this is 
transported and presented on the surface of the bacterium. (b) Model of N-linked 
glycoprotein assembly in Campylobacter jejuni; GTs sequentially build a heptasaccharide 
on undecaprenyl pyrophosphate; this is flipped into the periplasmic compartment of the cell 
before PglB using the UndPP linked sugar as a substrate, transfers it onto an acceptor 
protein (Peb3) within the acceptor sequon D/E-X1-N-X2-S/T. (c) Protein glycan coupling 
technology; plasmids coding for a carrier protein (CP), the OTase (PglB) and a 
polysaccharide of choice (PS) are transformed into a laboratory strain of E. coli, expressing 
the genetic contents of the three plasmids within an E. coli strain lacking WaaL allows for 
glycoconjugate vaccine production (GP). Cy, cytoplasm; IM, inner membrane; P, periplasm; 
OM, outer membrane; (n) indicates polymerisation status of polysaccharide.
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Figure 4. 
Major classes of N-linked glycans. N indicates the asparagine residues onto which the 
reducing end sugar is attached. GlcNAc is N-acetyl glucosamine; NeuAc is N-acetyl 
neuraminic acid. Boxed area indicates core pentasaccharide structure present in all 
eukaryotic glycans.
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Figure 5. 
Schematic demonstrating prokaryotic assembly of the eukaryotic glycan pentasaccharide 
core and transfer to an acceptor protein. WecA attaches GlcNAc to UndP, Alg13/14 add a 
second GlcNAc residue, before Alg1 and Alg2 attach three mannose residues to generate 
GlcNAc2Man3 core. The Escherichia coli flippase, Wzx, then moves the UndPP 
pentasaccharide to the periplasmic compartment of the cell where upon recognition by PglB, 
the glycan moiety is transferred to GP within the acceptor sequon D-X-N-X-S/T. GP, 
glycoprotein.
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Table 1
Publications related to utilisation of N-linked glycosylation for glycoconjugate vaccine and humanised 
glycoprotein production
Study Key findings
Production of glycoprotein vaccines in 
Escherichia coli. By Ihssen et al.[35]
First report of a glycoconjugate vaccine generated using PGCT. Shigella dysenteriae O1 antigen 
coupled to EPA.
Exploitation of bacterial N-linked 
glycosylation to develop a novel 
recombinant glycoconjugate vaccine 
against Francisella tularensis. By Cuccui 
et al.[36]
Stepwise demonstration of glycoconjugate vaccine development and efficacy testing in animal 
models. Francisella tularensis subs. tularensis O-antigen coupled to EPA.
Prevention of Staphylococcus aureus 
infections by glycoprotein vaccines 
synthesized in Escherichia coli. By 
Wacker et al.[37]
First demonstration of glycoconjugate vaccines developed against a Gram-positive organisms. 
Demonstration of efficacy using Staphylococcus aureus serotype 5 and 8 capsular polysaccharide 
attached to EPA as the carrier protein and demonstration of increased efficacy when the carrier 
protein is switched to the S. aureus-specific protein Hla.
An engineered eukaryotic protein 
glycosylation pathway in Escherichia coli. 
By Valderrama-Rincon et al.[53]
Demonstration of humanised glycoprotein production within Escherichia coli by combining E. 
coli, Saccharomyces cerevisiae and Campylobacter jejuni enzymes. Eukaryotic core 
pentasaccharide Man3GlcNAc2 assembled and transferred onto the eukaryotic proteins IgG1, 
bovine RNase A and human growth hormone.
A two-step enzymatic glycosylation of 
polypeptides with complex N-glycans. By 
Lomino et al.[56]
Utilised a novel N-linking glycosyltransferase from Actinobacillus pleuropneumoniae to form a 
priming sugar onto which complex N-glycans could be assembled in vitro through the use of an 
endoglycosidase (ENGase) catalysed transglycosylation. This method was used to generate a 
complex glycoform on an HIV inhibitor.
Exploiting bacterial glycosylation 
machineries for the synthesis of a Lewis 
antigen-containing glycoprotein. By Hug 
et al.[57]
By combining WecA from Escherichia coli to attach GlcNAc onto the lipid carrier UndPP and 
the Haemophilus influenzae lipooligosaccharide (LOS) biosynthesis cluster a precursor 
glycolipid GalGlcNAcGalGlcNAc-UndPP was formed and transferred to the acceptor protein 
AcrA. Addition of the fucose residue to the exterior GlcNAc residue by Helicobacter pylori FucT 
in vitro completed the synthesis of the Lewis x-glycoprotein.
A combined method for producing 
homogeneous glycoproteins with 
eukaryotic N-glycosylation. By Schwarz et 
al.[58]
Humanised glycoprotein were generated by altering the Pgl locus from Campylobacter jejuni. A 
(GalNAc)5GlcNAc-PP-undecaprenyl scaffold was assembled and presenting this hexasaccharide 
to PglB within an Escherichia coli cell resulted in transfer to an acceptor protein. Finally, in-vitro 
endoglycosidase-catalysed transglycosylation using pre-assembled N-glycan species as substrates 
gave rise to a homogenous pool of glycoproteins.
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